The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.

Ultra-low-pass whole genome sequencing (ULP-WGS) of circulating tumor DNA appears to provide important prognostic information regarding patients with large B-cell lymphoma (LBCL), according to ...

Whole-genome sequencing (WGS) of tumor and germline can generate actionable molecular insights that can guide precision medicine efforts in salivary gland cancer (SGC), according to a new study in JCO ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...